Skip to Main Content

Paper Details

Trastuzumab Deruxtecan, Antibody-Drug Conjugate Targeting HER2, Is Effective in Pediatric Malignancies: A Report by the Pediatric Preclinical Testing Consortium.
Mol Cancer Ther
5
2022
CAR-T cells, DXd, EWS, Ewing sarcoma, HER2, HER2 mRNA, HER2 protein, HER2-expressing tumors, MRT, MRT models, NB, OS, Osteosarcoma, Pediatric Malignancies, RMS, Trastuzumab, WT, WT PDX models, Wilms tumor, brain tumors, flank tumors, humanized, humanized monoclonal HER2-targeting antibody, mRNA, malignant rhabdoid tumor, mice, mouse, neuroblastoma, patient, patients, pediatric tumor PDX models, rhabdomyosarcoma, solid tumors, topoisomerase 1, trastuzumab deruxtecan, tumor
Author NameAffiliation
Wendong ZhangUniversity of Texas MD Anderson Cancer Center
Edward A KolbNemours/Alfred I. duPont Hospital for Children
Malcolm A Smith
Malcolm A Smith
Raushan T KurmashevaGreehey Children's Research Cancer Institute
Peter J HoughtonGreehey Children's Research Cancer Institute
Richard GorlickUniversity of Texas MD Anderson Cancer Center
Richard GorlickUniversity of Texas MD Anderson Cancer Center
  • 1 - 8

Datasets

Release 1.2